Cardiol Therapeutics Inc. Research and Development Expense
Cardiol Therapeutics Inc. (CRDL) reported Research and Development Expense of CAD 14.02 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-31
| Period end | Research And Development Expense 12 month |
|---|---|
| 2025-12-31 | 14.02M CAD 40-F · filed 2026-03-31 |
| 2024-12-31 | 14.01M CAD 40-F · filed 2026-03-31 |
| 2023-12-31 | 14.22M CAD 40-F · filed 2025-03-31 |
| 2022-12-31 | 18.96M CAD 20-F · filed 2024-04-01 |
| 2021-12-31 | 10.87M CAD 20-F · filed 2024-04-01 |
| 2020-12-31 | 10.60M CAD 20-F · filed 2023-03-29 |